73 results about "Influenza A antigen" patented technology

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.

Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the genome of the pathogen. The vaccine may also be a DNA vaccine comprised of DNA encoding a protein of the pathogen. The Ii-Key hybrid peptide construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of the protein or portion thereof which is used in the vaccine. The Ii-Key construct may be administered in the form of a nucleic acid construct encoding the Ii-Key hybrid peptide. Priming with Ii-Key peptides enhances the immunogenicity of rHA protein and HA and HIV DNA vaccines. Methods are described relating to the use of Ii-Key hybrid constructs in vaccine protocols wherein the pathogen is HIV or Influenza A, including H5N1. Methods and compositions are described wherein the MHC Class II epitope of the Ii-Key hybrid is hemagglutinin encoded by Influenza A or the Gag protein encoded by HIV.

The invention provides a test kit for detecting nucleic acid of respiratory tract pathogens. The kit comprises a CRISPR-Cas detection system: crRNA, a primer pair, Cas protein and a nucleic acid probethat are described in the invention. The invention further provides a detection method of the nucleic acid of the respiratory tract pathogens, a combination of the crRNA and the primer pair and application of the combination. The test kit and the detection method disclosed by the invention can be used for directly observing results by naked eyes without depending on a large instrument, and detection can be realized under a mild condition, so that the detection is more convenient; the test kit and the detection method provided by the invention can be used for efficiently and rapidly detecting/diagnosing the respiratory tract pathogens (such as flu A, flu B and COVID-19), have relatively high specificity and sensitivity, and can be used for detecting and screening the respiratory tract pathogens, for example, rapidly distinguishing various respiratory tract pathogens including the flu A, the flu B and the COVID-19.

Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

The invention discloses a corona virus disease 2019 screening method and system based on deep learning. The corona virus disease 2019 screening method comprises the steps: detecting a lung lesion areaof CT by using a deep learning detection model, and conveying the lung lesion area of CT into a three-classification network, wherein three classifications comprise COVID-19, influenza A and non-infection symptoms; and through calculation processing, outputting a CT diagnosis result and a disease probability. According to the method, based on deep learning, characteristics of CT images are automatically learned to distinguish COVIDI-19, influenza A and healthy people, so that the method is high in accuracy, the overall accuracy of current testing reaches 86.7%, the diagnosis speed is high, and only 30-60 S is needed for one set of CT according to different slice numbers; and a user can upload a CT image file and calculate and output a CT diagnosis result and the disease probability through the corona virus disease 2019 screening system, so that operation is convenient, the speed is high, and the detection rate of COVID-19 is greatly increased.

The invention discloses a multi-fluorescent PCR rapid detection kit for novel coronavirus, influenza A virus and influenza B virus. The kit comprises freeze-dried solid RT-PCR Mix, liquid redissolution Buffer, freeze-dried solid positive control and freeze-dried solid negative control, wherein the freeze-dried solid RT-PCR Mix contains a primer group corresponding to primer sequences of a SARS-CoV-2 specific gene ORF1ab, an influenza A M gene, an influenza B M gene and a human reference gene RNAse P. The kit combines a multi-fluorescent quantitative PCR technology and a freeze-drying process, utilizes three pairs of special primers and human reference genes to amplify specific sequences of three pathogens in vitro, and performs real-time detection in combination with a fluorescent probe. The detection method is simple and convenient to operate, has low requirements for the operation level of detection personnel, and can detect three common respiratory pathogens at a time, the detection time and the detection cost are greatly saved, rapid screening of large-batch samples is realized, the whole detection process only takes 40 minutes to 1 hours, and results are accurate and reliable.

The invention discloses a traditional Chinese medicine composite preparation. The composite traditional Chinese medicine composite preparation comprises the raw medicines in parts by weight of 5-20 parts of poria cocos, 5-10 parts of licorice roots, 5-20 parts of fructus aurantii, 5-20 parts of platycodon roots, 10-20 parts of radix bupleuri, 15-50 parts of plaster stones, 10-20 parts of rhizoma anemarrhenae, 10-20 parts of hogfennel roots, 10-20 parts of notopterygium incisum roots, 10-20 parts of rhizoma cimicifugae, 10-20 parts of divaricate saposhnikovia roots, 10-20 parts of fineleaf schizonepeta herbs, 10-20 parts of ligusticum wallichii, 10-30 parts of radix puerariae, 5-10 parts of mint, 15-30 parts of honeysuckle flowers, 15-30 parts of fructus forsythiae, 10-20 parts of wrinkledgianthyssop herbs, 5-15 parts of herba ephedrae and 10-30 parts of swordlike atractylodes rhizomes. The traditional Chinese medicine composite preparation has the effects of expelling pathogenic factors from the exterior, relieving exterior syndromes, promoting the dispersing function of the lung, dissipating dampness, removing toxin, clearing away the lung and the like, can be used for treating viral pneumonia caused by influenza A, and can have obvious healing effects on typical symptoms of the influenza A, including fever, discomfort or pain in throat, cough and the like. According to the traditional Chinese medicine composite preparation, common traditional Chinese medicines are used as raw materials, the advantage that the traditional Chinese medicines are low in toxic and side effects is exerted, and the traditional Chinese medicine composite preparation is safe, effective, cheap, and easy to broadly generalize, and has high clinical application value.

Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC) in combination with antisense oligonucleotides (AS) act synergistically in post-exposure prophylaxis or therapy of influenza infections, especially H5N1 virus infections.

Methods for the rapid detection of the presence or absence of SARS-CoV-2 in biological or non-biological samples are described. These methods are adapted to be performed rapidly in a point-of-care setting. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Specifically, primers and probes targeting SARS-CoV-2 are provided that are designed for the detection of this target. Additionally, kits and reaction vessels containing primers and probes targeting SARS-CoV-2 are provided. Additionally, methods, kits and reaction vessels for the simultaneous rapid detection of the presence or absence of SARS-CoV-2, influenza A, and influenza B in biological or non-biological samples are described.